Peer Review History

Original SubmissionJanuary 25, 2021
Decision Letter - Berlin Londono, Editor

PONE-D-21-02674

Descriptive analysis of surveillance data for Zika virus disease and Zika virus-associated neurological complications in Colombia, 2015-2017

PLOS ONE

Dear Dr. Charniga,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Apr 11 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Berlin Londono

Academic Editor

PLOS ONE

Journal Requirements:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see http://www.bmj.com/content/340/bmj.c181.long for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

We will update your Data Availability statement on your behalf to reflect the information you provide.

3. We note that Figures 2 and 6 in your submission contain map images which may be copyrighted. All PLOS content is published under the Creative Commons Attribution License (CC BY 4.0), which means that the manuscript, images, and Supporting Information files will be freely available online, and any third party is permitted to access, download, copy, distribute, and use these materials in any way, even commercially, with proper attribution. For these reasons, we cannot publish previously copyrighted maps or satellite images created using proprietary data, such as Google software (Google Maps, Street View, and Earth). For more information, see our copyright guidelines: http://journals.plos.org/plosone/s/licenses-and-copyright.

We require you to either (1) present written permission from the copyright holder to publish these figures specifically under the CC BY 4.0 license, or (2) remove the figures from your submission:

3.1.    You may seek permission from the original copyright holder of Figures 2 and 6 to publish the content specifically under the CC BY 4.0 license. 

We recommend that you contact the original copyright holder with the Content Permission Form (http://journals.plos.org/plosone/s/file?id=7c09/content-permission-form.pdf) and the following text:

“I request permission for the open-access journal PLOS ONE to publish XXX under the Creative Commons Attribution License (CCAL) CC BY 4.0 (http://creativecommons.org/licenses/by/4.0/). Please be aware that this license allows unrestricted use and distribution, even commercially, by third parties. Please reply and provide explicit written permission to publish XXX under a CC BY license and complete the attached form.”

Please upload the completed Content Permission Form or other proof of granted permissions as an "Other" file with your submission.

In the figure caption of the copyrighted figure, please include the following text: “Reprinted from [ref] under a CC BY license, with permission from [name of publisher], original copyright [original copyright year].”

3.2.    If you are unable to obtain permission from the original copyright holder to publish these figures under the CC BY 4.0 license or if the copyright holder’s requirements are incompatible with the CC BY 4.0 license, please either i) remove the figure or ii) supply a replacement figure that complies with the CC BY 4.0 license. Please check copyright information on all replacement figures and update the figure caption with source information. If applicable, please specify in the figure caption text when a figure is similar but not identical to the original image and is therefore for illustrative purposes only.

The following resources for replacing copyrighted map figures may be helpful:

USGS National Map Viewer (public domain): http://viewer.nationalmap.gov/viewer/

The Gateway to Astronaut Photography of Earth (public domain): http://eol.jsc.nasa.gov/sseop/clickmap/

Maps at the CIA (public domain): https://www.cia.gov/library/publications/the-world-factbook/index.html and https://www.cia.gov/library/publications/cia-maps-publications/index.html

NASA Earth Observatory (public domain): http://earthobservatory.nasa.gov/

Landsat: http://landsat.visibleearth.nasa.gov/

USGS EROS (Earth Resources Observatory and Science (EROS) Center) (public domain): http://eros.usgs.gov/#

Natural Earth (public domain): http://www.naturalearthdata.com/

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: This study sought to describe the prevalence of neurological complications of Zika virus disease (ZVD) in Colombia reported during the 2015-2017 epidemic. The authors used an extensive and large dataset to address question of neurological complications from ZVD. Considering that Zika virus is now endemic in many countries, the current study provides important insights to understanding the risk of ZVD for those living in and traveling to those areas. The authors are to be commended for their thorough study and summary of the data, however, I have a few comments which I would like for the authors to consider before publication. My comments are outlined below.

1. The authors should describe the evidence for Zika virus (ZKV) being neurotrophic. Evidence of ZKV neurotropism is not only found in patients with Guillain-Barré syndrome (GBS) or congenital zika virus syndrome (CZS), but there is preclinical evidence from animal studies showing that zika virus can infect the central nervous system in both young and adult animals (rodents and nonhuman primates). Explaining the evidence for neurotropism can help to explain why more neurologic symptoms beyond GBS should be investigated after ZKV infection in patients (Discussion pg 16 ln 371-379).

2. According to the current study data the highest incidents of ZVD is shown in adults. However, the data also shows that children of both sexes are equally susceptible to ZVD. In fact, a recent prospective study of children in Columbia (Pacheco et al, 2021, Paediatr Perinat Epidemiol, 35: 92-97) demonstrates that 15% of children infected with Zika virus between 1-12 month of age had adverse neurologic, hearing or eye examinations at 20 - 30 months of age. An additional 12.8% received an alert score in the hearing domain. Considering the neurotropism of the virus and the considerable postnatal development from birth to young adulthood, it is important to include broader surveillance of this young population other than severe neurological complications (see also recent review Raper & Chahroudi, 2021, Trop Med Infect Dis, 6 (10): 1-12).

3. Discussion pg 14 Ln 331-334, the authors should briefly mention that the possibility of prior immunity is also not possible due to the timing and origins of the virus arriving in Latin America from French-Polynesia.

4. Discussion pg 14 Ln 344-346, if spending more time at home is an increased risk of mosquito bite and ZVD in older females, would this also be the case for young children?

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Revision 1

Regarding data availability, we have revised our statement in lines 432-440:

The neurological complications dataset cannot be shared publicly as the data contain information on a small number of patients. Although the data are anonymized, identification is a risk given the high geographic resolution and large combination of predictor variables. This determination was made by Comité de Ética y Metodologías de Investigación (CEMIN). To request access to these data, please contact: secretariactin-cein@ins.gov.co, (57+1) 2207700 Ext. 1331-1108, Colombia. The aggregated ZIKV dataset is available on GitHub: https://github.com/kcharniga/descriptive_zika. The data include the number of weekly reported cases by administrative level 2 (municipality) as well as sex and age category.

The GitHub repository is currently set to private mode. If the paper is accepted for publication, the GitHub repository will be made public.

Regarding Figures 2 and 6, the maps were originally created using GADM version 2. However, we have now replaced them with maps created using shapefiles from the Humanitarian Data Exchange (https://data.humdata.org). These data are available under a Creative Commons Attribution for Intergovernmental Organizations (CC BY-IGO) license (https://data.humdata.org/about/license), which is compatible with CC BY 4.0. The figure legends have been updated accordingly.

In response to Reviewer 1:

Comment 1: The authors should describe the evidence for Zika virus (ZKV) being neurotrophic. Evidence of ZKV neurotropism is not only found in patients with Guillain-Barré syndrome (GBS) or congenital zika virus syndrome (CZS), but there is preclinical evidence from animal studies showing that zika virus can infect the central nervous system in both young and adult animals (rodents and nonhuman primates). Explaining the evidence for neurotropism can help to explain why more neurologic symptoms beyond GBS should be investigated after ZKV infection in patients (Discussion pg 16 ln 371-379).

We fully agree with this comment and have added additional information about the neurotropism of ZIKV to lines 390-395.

Comment 2: According to the current study data the highest incidents of ZVD is shown in adults. However, the data also shows that children of both sexes are equally susceptible to ZVD. In fact, a recent prospective study of children in Columbia (Pacheco et al, 2021, Paediatr Perinat Epidemiol, 35: 92-97) demonstrates that 15% of children infected with Zika virus between 1-12 month of age had adverse neurologic, hearing or eye examinations at 20 - 30 months of age. An additional 12.8% received an alert score in the hearing domain. Considering the neurotropism of the virus and the considerable postnatal development from birth to young adulthood, it is important to include broader surveillance of this young population other than severe neurological complications (see also recent review Raper & Chahroudi, 2021, Trop Med Infect Dis, 6 (10): 1-12).

We would like to thank the reviewer for suggesting these references. In lines 94-97, we have added additional information about postnatal transmission of ZIKV. We have also added the findings from the Pacheco et al. study to lines 417-420.

Comment 3: Discussion pg 14 Ln 331-334, the authors should briefly mention that the possibility of prior immunity is also not possible due to the timing and origins of the virus arriving in Latin America from French-Polynesia.

We thank the reviewer for this comment and have made the adjustment to lines 338-339.

Comment 4: Discussion pg 14 Ln 344-346, if spending more time at home is an increased risk of mosquito bite and ZVD in older females, would this also be the case for young children?

The reviewer makes a valid point. We agree, and have expanded our discussion of household-based exposure to mosquito bites in lines 356-359.

Attachments
Attachment
Submitted filename: Peer Review Response Letter.docx
Decision Letter - Berlin Londono, Editor

Descriptive analysis of surveillance data for Zika virus disease and Zika virus-associated neurological complications in Colombia, 2015-2017

PONE-D-21-02674R1

Dear Dr. Charniga,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Berlin Londono

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: No

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: I thank the authors for thoroughly addressing all of my comments and congratulations on this excellent work.

Reviewer #2: The manuscript is well written and conclusions are supported by the data. Authors have also addressed all the reviewer's questions satisfactorily.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Formally Accepted
Acceptance Letter - Berlin Londono, Editor

PONE-D-21-02674R1

Descriptive analysis of surveillance data for Zika virus disease and Zika virus-associated neurological complications in Colombia, 2015-2017

Dear Dr. Charniga:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Berlin Londono

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .